LOS ANGELES, CA--(Marketwire - Dec 20, 2011) - Among the few advances in improved treatments for brain cancers presented to the 1,400 Neuro-oncologists and other cancer researchers who met recently in Anaheim for the Annual Society of Neuro-oncology (SNO) meeting were Celldex's CDX-110 and Immunocellular Therapeutics' (OTCBB: [ IMUC ]) ICT-107.

Some summaries on the conference which may provide insights into new developments in new treatments for brain cancers are provided in a newly published Expert Briefing. Some of the most promising approaches were in the area of immunotherapy/vaccines, and were featured during several standing room only sessions. Investors can now read about some of the insights into these new developments.

The full Expert Briefing report, including information about the combination of vaccines and immune modulators, is available now at:

[ http://www.biomedreports.com/2011122086123/improved-treatments-for-brain-cancers-highlighted-at-annual-society-of-neuro-oncology-sno-meeting.html ]

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:

[ http://biomedreports.com/fdacal.html ]

News developments and live healthcare sector updates are available constantly via twitter at: [ http://twitter.com/BioMedReports ]

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com